ONL1204 is an investigational medication being studied for treating geographic atrophy (GA), a severe form of age-related macular degeneration (AMD) that can lead to vision loss. The medication is administered through injections and is designed to help slow down or prevent the progression of geographic atrophy in patients with AMD. This is a new treatment being tested to potentially help preserve vision in people affected by this condition.

The trial also includes sham injections as a control measure, which means some participants receive a simulated procedure without actual medication to compare the effectiveness of ONL1204.

Age-related Macular Degeneration (AMD) – A progressive eye condition that affects the central part of the retina called the macula. The disease exists in two forms, with the atrophic (dry) form characterized by the gradual breakdown of light-sensitive cells in the macula. In atrophic AMD, small yellow deposits called drusen develop under the retina, and the macula slowly thins and degenerates over time. This leads to the development of geographic atrophy (GA), where patches of retinal tissue deteriorate, creating areas of vision loss in the central field of vision. The condition typically develops gradually over several years, primarily affecting people over the age of 50. Vision changes occur slowly, with affected individuals experiencing increasing difficulty with detailed tasks like reading or recognizing faces.